Items per page
Sort by

Send to:

Choose Destination

Results: 19

Cited In for PubMed (Select 21795336)


A substitution in the transmembrane region of the glycoprotein leads to an unstable attenuation of Machupo virus.

Patterson M, Koma T, Seregin A, Huang C, Miller M, Smith J, Yun N, Smith J, Paessler S.

J Virol. 2014 Sep;88(18):10995-9. doi: 10.1128/JVI.01007-14. Epub 2014 Jul 16.


RIG-I enhanced interferon independent apoptosis upon Junin virus infection.

Kolokoltsova OA, Grant AM, Huang C, Smith JK, Poussard AL, Tian B, Brasier AR, Peters CJ, Tseng CT, de la Torre JC, Paessler S.

PLoS One. 2014 Jun 11;9(6):e99610. doi: 10.1371/journal.pone.0099610. eCollection 2014.


Potent inhibition of Junín virus infection by interferon in murine cells.

Huang C, Walker AG, Grant AM, Kolokoltsova OA, Yun NE, Seregin AV, Paessler S.

PLoS Negl Trop Dis. 2014 Jun 5;8(6):e2933. doi: 10.1371/journal.pntd.0002933. eCollection 2014 Jun.


Evolution of recombinant lymphocytic choriomeningitis virus/Lassa virus in vivo highlights the importance of the GPC cytosolic tail in viral fitness.

Sommerstein R, Ramos da Palma J, Olschläger S, Bergthaler A, Barba L, Lee BP, Pasquato A, Flatz L.

J Virol. 2014 Aug;88(15):8340-8. doi: 10.1128/JVI.00236-14. Epub 2014 May 14.


Watching every step of the way: junín virus attenuation markers in the vaccine lineage.

Stephan BI, Lozano ME, Goñi SE.

Curr Genomics. 2013 Nov;14(7):415-24. doi: 10.2174/138920291407131220153526.


Comparative analysis of disease pathogenesis and molecular mechanisms of New World and Old World arenavirus infections.

McLay L, Liang Y, Ly H.

J Gen Virol. 2014 Jan;95(Pt 1):1-15. doi: 10.1099/vir.0.057000-0. Epub 2013 Sep 25. Review.


Generation of recombinant arenavirus for vaccine development in FDA-approved Vero cells.

Cheng BY, Ortiz-Riaño E, de la Torre JC, Martínez-Sobrido L.

J Vis Exp. 2013 Aug 1;(78). doi: 10.3791/50662.


Vaccines for viral hemorrhagic fevers--progress and shortcomings.

Falzarano D, Feldmann H.

Curr Opin Virol. 2013 Jun;3(3):343-51. doi: 10.1016/j.coviro.2013.04.007. Epub 2013 Jun 15. Review.


Vaccination strategies against highly pathogenic arenaviruses: the next steps toward clinical trials.

Olschläger S, Flatz L.

PLoS Pathog. 2013;9(4):e1003212. doi: 10.1371/journal.ppat.1003212. Epub 2013 Apr 11. Review.


Targeting virulence mechanisms for the prevention and therapy of arenaviral hemorrhagic fever.

McLay L, Ansari A, Liang Y, Ly H.

Antiviral Res. 2013 Feb;97(2):81-92. doi: 10.1016/j.antiviral.2012.12.003. Epub 2012 Dec 20. Review.


Biochemical reconstitution of hemorrhagic-fever arenavirus envelope glycoprotein-mediated membrane fusion.

Thomas CJ, Shankar S, Casquilho-Gray HE, York J, Sprang SR, Nunberg JH.

PLoS One. 2012;7(11):e51114. doi: 10.1371/journal.pone.0051114. Epub 2012 Nov 30.


Advanced vaccine candidates for Lassa fever.

Lukashevich IS.

Viruses. 2012 Oct 29;4(11):2514-57. doi: 10.3390/v4112514. Review.


Junín virus pathogenesis and virus replication.

Grant A, Seregin A, Huang C, Kolokoltsova O, Brasier A, Peters C, Paessler S.

Viruses. 2012 Oct 19;4(10):2317-39. doi: 10.3390/v4102317. Review.


Severe hemorrhagic fever in strain 13/N guinea pigs infected with Lujo virus.

Bird BH, Dodd KA, Erickson BR, Albariño CG, Chakrabarti AK, McMullan LK, Bergeron E, Ströeher U, Cannon D, Martin B, Coleman-McCray JD, Nichol ST, Spiropoulou CF.

PLoS Negl Trop Dis. 2012;6(8):e1801. doi: 10.1371/journal.pntd.0001801. Epub 2012 Aug 28.


Reverse genetics recovery of Lujo virus and role of virus RNA secondary structures in efficient virus growth.

Bergeron É, Chakrabarti AK, Bird BH, Dodd KA, McMullan LK, Spiropoulou CF, Nichol ST, Albariño CG.

J Virol. 2012 Oct;86(19):10759-65. doi: 10.1128/JVI.01144-12. Epub 2012 Jul 25.


Drug discovery technologies and strategies for Machupo virus and other New World arenaviruses.

Radoshitzky SR, Kuhn JH, de Kok-Mercado F, Jahrling PB, Bavari S.

Expert Opin Drug Discov. 2012 Jul;7(7):613-32. doi: 10.1517/17460441.2012.687719. Epub 2012 May 19. Review.


The curious case of arenavirus entry, and its inhibition.

Nunberg JH, York J.

Viruses. 2012 Jan;4(1):83-101. doi: 10.3390/v4010083. Epub 2012 Jan 13. Review.


Substitutions in the glycoprotein (GP) of the Candid#1 vaccine strain of Junin virus increase dependence on human transferrin receptor 1 for entry and destabilize the metastable conformation of GP.

Droniou-Bonzom ME, Reignier T, Oldenburg JE, Cox AU, Exline CM, Rathbun JY, Cannon PM.

J Virol. 2011 Dec;85(24):13457-62. doi: 10.1128/JVI.05616-11. Epub 2011 Oct 5.


Junin virus infects mouse cells and induces innate immune responses.

Cuevas CD, Lavanya M, Wang E, Ross SR.

J Virol. 2011 Nov;85(21):11058-68. doi: 10.1128/JVI.05304-11. Epub 2011 Aug 31.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk